Prevnar 13 gets nod for pneumonia care in senior market

Share this content:
Prevnar 13 gets nod for pneumonia care in senior market
Prevnar 13 gets nod for pneumonia care in senior market

Pfizer Inc. announced that the Food and Drug Administration approved Prevnar 13 to prevent pneumococcal disease in older adults. The announcement “offers the potential to contribute to the health of millions of aging Americans,” said Ian Read, Pfizer's chairman and CEO. The vaccine had previously been approved for use in children up to five years old.